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Background: Clinical outcome in patients with severe traumatic brain injury (TBI) depends on both primary and secondary brain injuries. Neuroinflammation is an important secondary mechanism, which occurs by releasing interleukins (ILs). Increased levels of ILs may affect clinical outcome following TBI.
Objectives: This study aimed to determine the relationship between the serum levels of interleukins 6, 8 and 10 and clinical outcome in patients with severe TBI 6 months after injury.
Patients and Methods: In a descriptive-analytical study, 44 patients with GCS ≤ 8 (Glasgow coma scale) and age ≥ 14 years were included. Their blood samples were collected at first 6 hours after injury. Clinical outcome was determined based on GOS (Glasgow Outcome Scale) at 6 months after head injury. Serum levels of interleukins 6, 8 and 10 were measured using the ELISA method. Spearman's rho, independent T-Test, and Mann-Whitney Test were used for data analysis.
Results: Comparing the serum levels of interleukins in two groups with favorable and unfavorable clinical outcomes showed that the mean serum levels of interleukins 6 and 8 in group with favorable outcome was 85.2 ± 51.6 and 52.2 ± 31.9, respectively lower than those of group with unfavorable outcome with 162.3 ± 141.1 and 173.6 ± 257.3 (P < 0.03) and (P < 0.01).
Conclusions: Increased serum levels of interleukins 6 and 8 as a predictive marker might be associated with unfavorable clinical outcome in patients with severe TBI.
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1. BackgroundTraumatic brain injury (TBI) is one of the leading causes of morbidity and mortality worldwide particularly among young people and imposes high costs directly and indirectly on societies (1). Based on reports provided by United States Centers for Disease Control and Preven-tion, 1.7 million victims suffer from traumatic brain inju-ry and its complications (2) . Studies have shown that the outcome of patients with TBI is determined by severity of primary injury and extent of secondary brain damage (SBD) (3). The mechanisms of primary injury are caused by mechanical injury to neurons, axons, glia and blood vessels. These effects induce secondary mechanisms which result from depolarization (4), neurotransmitters release (5), lipids disturbance (6) and delayed inflamma-tory and immunological response in minutes, days and even months after the primary injury (7). Inflammation 
following TBI can cause complications which may affect patient outcome including systemic inflammatory re-sponse syndrome (SIRS). This clinical syndrome is the result of extended activity of inflammatory pathways (8).Activated inflammatory cascade after TBI is mediated by release of pre and anti-inflammatory cytokines. These cytokines are polypeptides that are rarely observed in a healthy brain but their level rises rapidly in response to pathological or stressful conditions (8, 9). There is differ-ent types of cytokines including interleukin. Studies have indicated the pathological role of interleukins in both pe-ripheral and central nervous system (CNS) diseases such as shock, meningitis and head injury (10). Developments on understanding secondary injury provide new thera-peutic intervention to prevent progressive tissue dam-age and following dysfunction. To obtain effective neuro 
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protective treatments in TBI patients, understanding of complex cellular and molecular events which contribute to secondary injury is important. Neuro inflammation is a major secondary injury mechanism after TBI which re-sults in post-trauma sustained damage. However, experi-mental and clinical research proved that neuro inflam-mation after TBI can have both detrimental and beneficial effects which are probably different in acute and delayed phases. The key to developing future anti-inflammatory based neuro protective treatments for TBI is to reduce the detrimental and neurotoxic effects of neuro inflam-mation while promoting the beneficial and neurotropic effects, thereby creating optimal conditions for regenera-tion and repair after injury (11, 12). Many studies revealed that released interleukins affect clinical outcomes after brain injury and cause pre-inflammatory changes (13, 14). Interleukin 8 released from monocytes and endothelial cells involve in degeneration and regeneration (14, 15). In-terleukin 10 produced by macrophage and microglia has anti-inflammatory and immunosuppressant effect (14). Despite of significant improvements in organizing mea-sures related to traumatic brain injury to date, no effec-tive treatment is available for these patients so far and the rate of mortality and morbidity is high (1). Although acute inflammation plays an important role in patho-physiology of brain, the special relationship between mediators of inflammation and patient outcome after TBI has not been fully established yet (16).
2. ObjectivesThe aim of this study was to achieve a better under-standing of the effects of a number of interleukins which are inflammatory mediators on clinical outcome by ana-lyzing their serum levels in patients with severe TBI.
3. Patients and MethodsThis is a descriptive-analytical study conducted on 47 TBI patients with GCS ≤ 8, admitted to Poursina Teaching Hospital in Rasht (Guilan province). Out of total admit-ted patients, 3 were excluded because they were younger than 14 years old. The patients with underlying diseases were excluded from the study. The patients showed no additional medical problems during the time between the sampling and assessing the outcome. Blood samples were taken at first six hours after injury from 44 remain-ing patients, then the samples were centrifuged and the supernatant was immediately transferred to -80°C freezer and kept there until the test time. Measuring concentra-tions of interleukin 6, 8 and 10 in blood serum of patients was performed by ELISA (Enzyme Liked Immunosorbent Assay), which is a high sensitive method (Bender Med Sys-tem Co). Patients outcomes were determined 6 months after head injury based on Glasgow outcome scale (GOS) as death outcome, vegetative state, severe disability, mod-erate disability, and good recovery. Patients with moder-ate disability or recovery were categorized as favorable 
group and other patients put in unfavorable group. There was no difference in treatment method between both groups. Statistical analysis of all data including GCS on admission, age, sex, results of measurement of inter-lukines and their relation with patient outcome was con-ducted by SPSS software (version 18) using the Spearman's rho, Independent T-Test, Mann-Whitney Test. Differences were considered statistically significant at P ≤ 0.05.
4. ResultsFrom a total of 44 patients included in this study, 97.7% were male and the rest were female with the mean ages of 33.7 ± 17.6 years. Accidents caused by motor vehicle crash-es (97.7%) were the most common cause of trauma. Re-sults of patients outcome at 6 months after head injury based on GOS showed that 56.4% of the patients died, 2.6% had vegetative life, 25.6% severe disability, 10.3% moderate disability, and 5.1% good recovery. Based on the previous classification, it can be said that 15.4% had favorable and 84.6% unfavorable outcome. Mean ages in favorable and unfavorable outcome groups were 36.7 ± 8.6 and 33.1 ± 17.5, respectively and there was no statistically significant correlation between mean age of groups. Mean GCS at ad-mission time in group with favorable outcome was 5.7 ± 1.7, while in other group, mean GCS was 5.1 ± 1.5 suggest-ing that there is no statistically significant correlation. Serum levels of interleukin 8 (P < 0.01) and interleukin 6 (P < 0.03) were significantly higher in groups with unfa-vorable outcomes comparing to favorable outcome; how-ever, no statistically significant difference was observed in serum level of IL -10 in the two groups (Table 1). Table 1 displays that the mean of serum level of inter-leukins 6 and 8 in group with favorable outcome (85.251.6 pg/mL and 52.231.9 pg/mL, respectively) that was less than that of group with unfavorable outcome (162.3141.1 pg/mL and 173.6257.3 pg/mL).Studying the correlations between serum level of interleukins at time of measurement and GCS on admission, the results of Spearman correlation coefficient test revealed a statistically negative correla-tion between GCS at admission and serum level of inter-leukin 8 (P < 0.01) , no statistically correlation was found between GCS at admission and serum level of IL 6 and IL 10 (Table 2).
Table 1.  Serum Levels of Interleukins in the Traumatic Brain Injury (TBI) Patients per Outcome a,b
Interleukin, 
pg/mL
Favorable 
Outcome
Unfavorable 
Outcome
P-Value c
IL-6 85.2 ± 51.6 162.3 ± 141.1 0.03
IL-8 162.3 ± 141.1 173.6 ± 257.3 0.01
IL_10 52.2 ± 31.9 83.9 ± 79.4 0.9a Abbreviation: IL, Interleukin.b Values are expressed as Mean ± SE.c P value obtained by Independent T-test for the difference between the two groups.
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Table 2.  Relationship Between GCS at Admission With Serum Levels of Interleukins
Variables R P-Value
GCS IL-6 -0.33 0.05
GCS IL-8 -0.43 0.01
GCS IL-10 0.08 0.6
5. DiscussionRelationship between clinical status and neuro inflam-mation was found through measuring inflammatory markers in plasma and cerebrospinal fluid (CSF) (17). Due to importance of inflammation process in clinical sta-tus of patient in this study, we attempted to find more information about the role of cytokines including inter-leukins 6, 8 and 10 in clinical outcome after head injury by measuring serum levels in patients with severe TBI. Our study showed that the mean serum level of IL-6 in patients with unfavorable outcome was more than that of patients with favorable outcome. Results of a study by Chiaretti et al. were compatible with those of our study. They reached this conclusion by evaluating the levels of this interleukin in CSF and serum of children with severe TBI that increased in IL-6 expression which was indicative of poor clinical outcome (18). Moreover, Antunes et al. observed a remarkable difference in mean plasma levels of IL-6 in both favorable and unfavorable outcomes; the highest levels of IL-6 was observed in patients with worst clinical course (19). In a study by Kalabalikis et al. on levels of IL-6 in serum of children with head injury, no relation-ship was found between IL-6 and patient outcome (20). However, the results of several studies on measuring IL-6 levels in CSF of TBI patients showed that increased levels of this interleukin was associated with favorable clini-cal outcome in patients (16, 21). In addition, IL-6 levels in CSF might be associated with favorable clinical outcome whereas measuring serum levels indicated association with unfavorable clinical outcome. Such results show the complexity of neuroinflammation response to TBI and emphasize the fact that cytokines can play multiple roles under different conditions in CSF and peripheral blood circulation (8). In present study, measuring serum levels of interleukin-8 and its relationship with patient outcome revealed that the mean serum level of IL-8 in pa-tients with unfavorable outcome was more than that of patients with favorable outcome. A research by Michael Whalen and colleagues also showed remarkable increase in levels of IL-8 in CSF of children with severe head injury. These high concentrations were associated with mortal-ity in children (15). According to our results, although the mean serum level of IL-10 in patients with unfavorable outcome was more than that of patients with favorable outcome, this difference was not statistically signifi-cant. In this regard, the results of a study by Shiozaki et al. showed that IL-10 concentration in CSF in patients 
with unfavorable outcome was remarkably higher than that of patients with favorable outcome (22). Consider-ing the relationship between these interleukins and pa-tient outcome, Bernd Maier et al. found no significant relationship between interleukins 6, 8 and 10 and clini-cal outcome (based on GOS) 6 months after head injury (23). Similar results were observed in a study by Hayakata and colleagues (24). Overall, it is concluded that the in-flammatory proteins according to when and where they are released with respect to their concentration can have both beneficial and detrimental effects (25). The results of present study on relationship between serum levels of interleukins and severe head injury based on GCS indicat-ed that only serum level of IL-8 was negatively correlated with GCS on admission. However, Hayakata et al. found no significant correlation between peaks of IL-8 concen-tration in CSF and GCS on admission in TBI patients in their study (24). Neuroinflammation occurs in response to traumatic brain injury. This response can affect patient clinical outcome by inflammatory markers such as inter-leukins. Based on findings of our study, increased levels of interleukins 6 and 8 in first hours after severe TBI were associated with unfavorable clinical outcome. Therefore, measuring serum levels of these interleukins may be considered as a marker for predicting patient clinical outcome following head injury. We hope that measuring and regulating neuro inflammatory response by these markers could be helpful in improving therapeutic strat-egies for TBI patients to reduce the rate of mortality and morbidity.
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